Risk of thyroid C-cell tumors. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2.
Incidence rates from clinical trials. Individual experience varies.
| Effect | Incidence | Note |
|---|---|---|
| Nausea | 12-18% | Dose-dependent, peaks during escalation |
| Diarrhea | 12-17% | |
| Vomiting | 5-13% | |
| Constipation | 6-9% | |
| Decreased appetite | 5-11% |
Less common but require medical attention.
Independently reviewed providers offering Tirzepatide for weight management. Editorial ranking — affiliate links don't affect order.
Board-certified obesity medicine physicians prescribing GLP-1s. Often insurance-covered — among the most affordable options when insurance applies.
Weight-inclusive primary care with GLP-1 access. Designed by clinicians frustrated with typical obesity medicine model — focuses on the whole person.
Doctor-led GLP-1 weight loss program. Offers compounded semaglutide/tirzepatide and FDA-approved Wegovy/Zepbound for eligible patients.
Whole-person weight loss with GLP-1 medication plus behavioral coaching. One of the larger GLP-1 telehealth programs.
Year-long metabolic health program combining GLP-1 medication with intensive 1:1 coaching. Premium price point, strong outcomes data.
We don't sell Tirzepatide or any medication. These are editorial reviews of telehealth providers — clicking through may earn us a commission, which does not affect our scoring.
Was this Tirzepatide side-effects guide helpful?